Education
About Us
Working with TipRanks
Follow Us
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
RESEARCH TOOLSreports
MAZE Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MAZE Stock 12 Month Forecast
Average Price Target
$26.75
▲(62.61%Upside)
| Highest Price Target$34.00 | Average Price Target$26.75 | Lowest Price Target$17.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$34
Buy
106.69%
Upside
Initiated
07/23/25
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued StockValuations and Risks. We assume the number of diagnosed AKD patients in the US is 142K that might be potentially treated by MZE829. We assume that MZE829 launches in the US in 2030. We project a peak penetration rate of 5% in 2035, which translates into approximately 8K patients on MZE829 in 2035. We assign a PoS of 15%. Assuming an annual cost of $130K at launch growing to $151K at 3% YoY price growth by 2035. We estimate total revenue to be around $1.2B. We estimate total probability adjusted revenue can reach $176M by 2035. For EU, we estimate a total revenue of $653M.
TD Cowen
―
Buy
―
Reiterated
07/21/25
Wedbush
$17
Buy
3.34%
Upside
Initiated
07/08/25
Leerink Partners
$28
Buy
70.21%
Upside
Reiterated
06/26/25
J.P. Morgan
$30→$28
Buy
70.21%
Upside
Reiterated
05/20/25
Guggenheim
$19
Buy
15.50%
Upside
Initiated
02/25/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$34
Buy
106.69%
Upside
Initiated
07/23/25
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued StockValuations and Risks. We assume the number of diagnosed AKD patients in the US is 142K that might be potentially treated by MZE829. We assume that MZE829 launches in the US in 2030. We project a peak penetration rate of 5% in 2035, which translates into approximately 8K patients on MZE829 in 2035. We assign a PoS of 15%. Assuming an annual cost of $130K at launch growing to $151K at 3% YoY price growth by 2035. We estimate total revenue to be around $1.2B. We estimate total probability adjusted revenue can reach $176M by 2035. For EU, we estimate a total revenue of $653M.
TD Cowen
―
Buy
―
Reiterated
07/21/25
Wedbush
$17
Buy
3.34%
Upside
Initiated
07/08/25
Leerink Partners
$28
Buy
70.21%
Upside
Reiterated
06/26/25
J.P. Morgan
$30→$28
Buy
70.21%
Upside
Reiterated
05/20/25
Guggenheim
$19
Buy
15.50%
Upside
Initiated
02/25/25
Best Analysts Covering Maze Therapeutics, Inc.
1 Month
xxx
Success Rate
3/4 ratings generated profit
Average Return
+17.00%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +17.00% per trade.
3 Months
xxx
Success Rate
3/4 ratings generated profit
Average Return
+28.90%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +28.90% per trade.
1 Year
Success Rate
4/4 ratings generated profit
Average Return
+52.98%
reiterated a buy rating last month
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +52.98% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
Average Return
+52.98%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +52.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MAZE Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
4
4
3
3
4
Buy
1
2
2
2
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
6
5
5
7
Each month's total comprises the sum of three months' worth of ratings.
MAZE Financial Forecast
MAZE Stock Forecast FAQ
What is MAZE’s average 12-month price target, according to analysts?
Based on analyst ratings, Maze Therapeutics, Inc.’s 12-month average price target is 26.75.
What is MAZE’s upside potential, based on the analysts’ average price target?
Maze Therapeutics, Inc. has 62.61% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MAZE a Buy, Sell or Hold?
Maze Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Maze Therapeutics, Inc.’s price target?
The average price target for Maze Therapeutics, Inc. is 26.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $34.00 ,the lowest forecast is $17.00. The average price target represents 62.61% Increase from the current price of $16.45.
The highest analyst price target is $34.00 ,the lowest forecast is $17.00. The average price target represents 62.61% Increase from the current price of $16.45.
What do analysts say about Maze Therapeutics, Inc.?
Maze Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of MAZE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.